Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategyKlas Kärre, Rolf Kiessling|Nature|1986Cited by 2.1k
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Enrico Lugli, Guido Kroemer et al.|Oncotarget|2014Cited by 469
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivoTadepally Lakshmikanth, Francesco Colucci, Shannon Burke et al.|Journal of Clinical Investigation|2009Cited by 331
The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cellsPetter Brodin, Petter Höglund, Tadepally Lakshmikanth et al.|Blood|2008Cited by 261
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2Hai Li, Galina Selivanova, Tadepally Lakshmikanth et al.|Cell Cycle|2011Cited by 118